Privium Fund Management B.V. Raises Stake in Moderna, Inc. (NASDAQ:MRNA)

Privium Fund Management B.V. boosted its stake in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) by 74.0% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 40,482 shares of the company's stock after purchasing an additional 17,221 shares during the quarter. Moderna comprises 0.7% of Privium Fund Management B.V.'s holdings, making the stock its 28th largest holding. Privium Fund Management B.V.'s holdings in Moderna were worth $2,705,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Ashton Thomas Private Wealth LLC bought a new stake in shares of Moderna in the 2nd quarter valued at about $26,000. Cedar Wealth Management LLC boosted its stake in Moderna by 45.0% in the first quarter. Cedar Wealth Management LLC now owns 290 shares of the company's stock valued at $31,000 after acquiring an additional 90 shares in the last quarter. Family Firm Inc. purchased a new position in Moderna in the second quarter worth $33,000. Bank & Trust Co purchased a new position in Moderna in the second quarter worth $36,000. Finally, Hanseatic Management Services Inc. acquired a new position in shares of Moderna during the second quarter worth $48,000. Hedge funds and other institutional investors own 75.33% of the company's stock.

Moderna Stock Down 6.9 %

NASDAQ MRNA traded down $3.45 during mid-day trading on Friday, reaching $46.83. 13,561,538 shares of the stock were exchanged, compared to its average volume of 5,571,917. The company has a debt-to-equity ratio of 0.05, a quick ratio of 3.92 and a current ratio of 4.39. The business's 50 day moving average is $61.85 and its 200-day moving average is $99.09. Moderna, Inc. has a 1 year low of $46.57 and a 1 year high of $170.47.

Moderna (NASDAQ:MRNA - Get Free Report) last posted its earnings results on Thursday, November 7th. The company reported $0.03 earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.89) by $1.92. Moderna had a negative net margin of 43.77% and a negative return on equity of 17.68%. The business had revenue of $1.90 billion for the quarter, compared to analyst estimates of $1.25 billion. During the same period in the prior year, the company posted ($1.39) EPS. The company's revenue for the quarter was up 3.8% on a year-over-year basis. On average, equities analysts forecast that Moderna, Inc. will post -9.89 earnings per share for the current year.

Insider Transactions at Moderna

In other news, CFO James M. Mock sold 715 shares of Moderna stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $60.12, for a total value of $42,985.80. Following the sale, the chief financial officer now owns 9,505 shares in the company, valued at $571,440.60. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other news, CFO James M. Mock sold 715 shares of the firm's stock in a transaction that occurred on Monday, October 7th. The stock was sold at an average price of $60.12, for a total value of $42,985.80. Following the transaction, the chief financial officer now owns 9,505 shares in the company, valued at $571,440.60. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO James M. Mock sold 1,321 shares of the business's stock in a transaction that occurred on Wednesday, August 28th. The stock was sold at an average price of $79.39, for a total value of $104,874.19. Following the sale, the chief financial officer now owns 8,600 shares of the company's stock, valued at $682,754. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 3,184 shares of company stock valued at $238,531 in the last three months. 15.70% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on MRNA shares. Deutsche Bank Aktiengesellschaft raised Moderna from a "sell" rating to a "hold" rating and lowered their price objective for the stock from $85.00 to $80.00 in a research report on Wednesday, August 7th. Leerink Partners cut their price objective on shares of Moderna from $60.00 to $48.00 and set an "underperform" rating on the stock in a report on Tuesday, September 17th. Hsbc Global Res upgraded shares of Moderna from a "moderate sell" rating to a "hold" rating in a research note on Wednesday, August 28th. Oppenheimer lowered shares of Moderna from an "outperform" rating to a "market perform" rating in a research note on Friday, September 13th. Finally, Jefferies Financial Group lowered their price objective on shares of Moderna from $65.00 to $55.00 and set a "hold" rating for the company in a research note on Tuesday, October 15th. Two equities research analysts have rated the stock with a sell rating, fourteen have given a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat, Moderna has an average rating of "Hold" and an average price target of $93.18.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.